-
公开(公告)号:US20060234222A1
公开(公告)日:2006-10-19
申请号:US10501357
申请日:2002-12-30
CPC分类号: C12N15/62 , C07K14/31 , C07K2319/00 , C07K2319/20 , C07K2319/21 , C07K2319/23 , C12N9/10 , C12N9/104 , C12N15/70 , C12P21/02
摘要: Described is a method of producing a soluble bioactive domain of a protein, the method comprising the step of selecting suitable soluble subunits of a protein and assessing the produced protein for desired activity. The method may comprise the steps of amplifying DNA encoding at least one candidate soluble domain, cloning the amplified DNA into at least one expression vector, using each of said vectors into which the DNA has been cloned to each transfect or transform one or more host cell strains, expressing said DNA in one or more host cell strains, and analyzing expression products from said host cells for solubility.
摘要翻译: 描述了产生蛋白质的可溶性生物活性结构域的方法,所述方法包括选择蛋白质的合适的可溶性亚基并评估产生的蛋白质以获得所需活性的步骤。 该方法可以包括以下步骤:使用编码至少一个候选可溶性结构域的DNA,将扩增的DNA克隆到至少一个表达载体中,使用已经将DNA克隆到其中的每个所述载体转染或转化一个或多个宿主细胞 菌株,在一个或多个宿主细胞株中表达所述DNA,并分析来自所述宿主细胞的表达产物的溶解度。
-
公开(公告)号:US20100104554A1
公开(公告)日:2010-04-29
申请号:US12281356
申请日:2007-03-02
申请人: Christopher Scott , Roberta Burden , Jim Johnston , Mark McCurley , Philip Snoddy , Richard Buick
发明人: Christopher Scott , Roberta Burden , Jim Johnston , Mark McCurley , Philip Snoddy , Richard Buick
IPC分类号: A61K39/395 , A61K38/48 , C12P21/06 , C12N9/64 , A61K38/00 , A61K31/7088
CPC分类号: A61K38/4873
摘要: A method of inhibiting activity of a cathepsin L-like protease in cells or tissue and the use of the method in the treatment of disease such as cancer and inflammatory diseases is described. The method comprises administration of a cathepsin propeptide or a nucleic acid encoding a cathepsin propeptide. In particular embodiments, the propeptide is a Cathepsin S propeptide. Further, the use of propeptides having an Fc portion is described.
摘要翻译: 描述了抑制组织蛋白酶L样蛋白酶在细胞或组织中的活性的方法以及该方法在治疗疾病如癌症和炎性疾病中的用途。 该方法包括给予组织蛋白酶前肽或编码组织蛋白酶前肽的核酸。 在具体实施方案中,前肽是组织蛋白酶S前肽。 此外,描述了使用具有Fc部分的前肽。
-
公开(公告)号:US08846868B2
公开(公告)日:2014-09-30
申请号:US12988135
申请日:2009-04-17
申请人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
发明人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
CPC分类号: C07K16/22 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/74 , A61K2300/00
摘要: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
摘要翻译: 描述了对AREG和HBEGF具有结合特异性的交叉特异性抗体分子。 抗体分子可用于治疗癌症和与血管发生相关的疾病的方法。
-
公开(公告)号:US20110150886A1
公开(公告)日:2011-06-23
申请号:US12988135
申请日:2009-04-17
申请人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
发明人: Jill Caswell , Shane Olwill , James Johnston , Richard Buick , Thomas Jaquin , Declan Doherty , Christopher Scott
IPC分类号: A61K39/395 , A61K31/7088 , A61P35/00 , C07K16/18 , C07H21/04
CPC分类号: C07K16/22 , A61K39/39558 , A61K2039/505 , C07K16/2863 , C07K2317/31 , C07K2317/33 , C07K2317/73 , C07K2317/74 , A61K2300/00
摘要: Described are cross-specific antibody molecules with binding specificity for both AREG and HBEGF. The antibody molecules may be used in methods of treatment of cancer and diseases associated with angiogenesis.
摘要翻译: 描述了对AREG和HBEGF具有结合特异性的交叉特异性抗体分子。 抗体分子可用于治疗癌症和与血管发生相关的疾病的方法。
-
公开(公告)号:US07939642B2
公开(公告)日:2011-05-10
申请号:US11918102
申请日:2006-04-10
申请人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
发明人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC分类号: C12P21/08
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
摘要翻译: 描述的是具体的结合成员,例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症,炎性疾病,神经变性疾病,自身免疫性疾病以及与过度,失调或不合适的血管生成相关的其它疾病的疾病。
-
公开(公告)号:US20090317405A2
公开(公告)日:2009-12-24
申请号:US11918102
申请日:2006-04-10
申请人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
发明人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC分类号: A61K39/395 , A61K31/7052 , C07K16/00 , C07H21/00 , C12P21/00 , A61P35/00 , A61P29/00 , A61P27/02 , A61K48/00
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
摘要翻译: 描述的是具体的结合成员,例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症,炎性疾病,神经变性疾病,自身免疫性疾病以及与过度,失调或不合适的血管生成相关的其它疾病的疾病。
-
公开(公告)号:US20110243955A1
公开(公告)日:2011-10-06
申请号:US13051497
申请日:2011-03-18
申请人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
发明人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC分类号: A61K39/395 , A61K31/7088 , C07K16/40 , C07H21/04 , A61P35/00 , A61P29/00 , A61P27/02 , A61P35/02 , A61P19/02 , A61P1/00 , A61P1/04 , A61P9/10 , C12P21/02
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis
摘要翻译: 描述的是具体的结合成员,例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症,炎性疾病,神经变性疾病,自身免疫性疾病和与过度,失调或不适当的血管生成相关的疾病
-
公开(公告)号:US08747849B2
公开(公告)日:2014-06-10
申请号:US13051497
申请日:2011-03-18
申请人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
发明人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC分类号: A61K39/395
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members bind cathepsin S and inhibit its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
摘要翻译: 描述的是具体的结合成员,例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症,炎性疾病,神经变性疾病,自身免疫性疾病以及与过度,失调或不合适的血管生成相关的其它疾病的疾病。
-
公开(公告)号:US20090068198A1
公开(公告)日:2009-03-12
申请号:US11918102
申请日:2006-04-10
申请人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
发明人: Christopher Scott , Roberta Burden , Shane Olwill , Brian Walker , Jim Johnston
IPC分类号: A61K39/395 , A61K31/7052 , C07K16/00 , C07H21/00 , C12P21/00 , A61P35/00 , A61P29/00 , A61P27/02
CPC分类号: C07K16/40 , A61K2039/505 , C07K2317/56 , C07K2317/76 , C07K2317/92
摘要: Described are specific binding members e.g. antibodies which may be used in the treatment of diseases associated with cathepsin S activity. The specific binding members binds cathepsin S and inhibits its proteolytic activity. The binding members may be used in the treatment of diseases such as cancer, inflammatory diseases, neurodegenerative disorders, autoimmune disorders, and other diseases associated with excessive, deregulated or inappropriate angiogenesis.
摘要翻译: 描述的是具体的结合成员,例如 可用于治疗与组织蛋白酶S活性相关的疾病的抗体。 特异性结合成员结合组织蛋白酶S并抑制其蛋白水解活性。 结合成员可用于治疗诸如癌症,炎性疾病,神经变性疾病,自身免疫性疾病以及与过度,失调或不合适的血管生成相关的其它疾病的疾病。
-
公开(公告)号:US20100111965A1
公开(公告)日:2010-05-06
申请号:US12445109
申请日:2007-10-11
申请人: James Johnston , Shane Olwill , Jill Brown , Nuala Morgan , Thomas Jaquin , Christopher Scott
发明人: James Johnston , Shane Olwill , Jill Brown , Nuala Morgan , Thomas Jaquin , Christopher Scott
IPC分类号: A61K39/395 , A61K31/7088 , C07K16/00 , A61P35/00 , C12Q1/68
CPC分类号: C12N15/1136 , A61K39/39558 , C07K16/22 , C07K2317/56 , C07K2317/73 , C12N2310/14 , C12N2320/31 , A61K2300/00
摘要: The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies.
摘要翻译: 本发明提供一种治疗受试者的肿瘤疾病的方法,所述方法包括向所述受试者施用有效量的(i)第一EGF的抑制剂,例如, HB-EGF和(ii)第二EGF的抑制剂,例如。 AREG。 还描述了EGF抑制剂与拓扑异构酶抑制剂的新的协同组合,其减弱肿瘤细胞生长。 进一步描述的是新的抗AREG抗体。
-
-
-
-
-
-
-
-
-